Loading
Life sciences · Journal article
Frontiers in Oncology · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cancer of unknown primary (CUP) is primarily treated with empirical chemotherapy, but clinical outcomes remain unsatisfactory. We present the case of a 62-year-old male with asymptomatic left supraclavicular lymphadenopathy. Fine-needle aspiration revealed metastatic poorly differentiated carcinoma. Comprehensive evaluation, including contrast-enhanced computed tomography (CT), fluorodeoxyglucose positron emission tomography/CT (FDG-PET/CT), nasopharyngoscopy, and gastroscopy, failed to identify a definite primary tumor, leading to a diagnosis of CUP. Initial empirical chemotherapy with liposomal paclitaxel and nedaplatin showed limited efficacy and was complicated by grade 3 treatment-related adverse events (TRAEs), resulting in discontinuation due to poor tolerability. Subsequently, a core needle biopsy was performed. Immunohistochemistry suggested metastatic renal cell carcinoma (RCC). A 90-gene expression assay identified the kidney as the most likely primary site, with a similarity score of 82.6. The regimen was then switched to site-specific therapy with lenvatinib plus camrelizumab. The patient tolerated treatment well, experiencing only grade 1 TRAEs. Follow-up contrast-enhanced CT scans demonstrated significant lesion regression (33.1% and 69.6% reductions at 2 and 4 months, respectively), achieving a best response of partial response (PR). In conclusion, the combination of lenvatinib and camrelizumab demonstrated a favorable short-term response and acceptable tolerability in this patient, and renal-like CUP represents a distinct favorable CUP subset.